Skip to main content
Top
Published in: Diagnostic Pathology 1/2019

Open Access 01-12-2019 | Prostate Cancer | Research

Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy

Authors: Young Hyo Choi, Ji Woong Yu, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Hwang Gyun Jeon

Published in: Diagnostic Pathology | Issue 1/2019

Login to get access

Abstract

Background

Pathological features of prostate cancer in Korean men were analyzed to determine whether identification of tumor volume, Gleason score (GS), focality, and location using radical prostatectomy (RP) specimens can provide useful information for the application of focal therapy (hemiablation).

Methods

From January 2016 to December 2017, 913 patients who underwent RP at a single center were selected for analysis. Patients with prostate-specific antigen levels > 15 ng/mL or those who had received hormone therapy prior to surgery were excluded. Preoperative data and the number, volume, location, and GS of each tumor were recorded.

Results

Overall, 762 RP specimens were examined, and 1448 tumors were identified. The majority of the cases were multifocal (60.5%) and bilateral (82%) in nature. Among the 686 secondary tumors, 250 (36.4%) had a GS ≥7 and 122 (17.8%) had a tumor volume ≥ 0.5 mL. Among the 435 bilateral multifocal cases, secondary tumors on the lobes contralateral to the largest tumor were significant by volume (≥0.5 mL) in 91 (20.9%) cases and by grade (GS ≥7) in 179 (41.1%) cases. There were 102 (23.4%) tumors with a small tumor volume (< 0.5 mL) and Gleason pattern 4 on the lobe contralateral to the largest tumor.

Conclusions

Bilateral and multifocal tumors are a common feature and secondary tumors frequently exhibit clinically significant prostate cancer on RP specimens in Korea. In many cases, secondary tumors on the lobe contralateral to the largest tumor had a high GS and small tumor volume.
Literature
1.
go back to reference van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM, Lam TB, Mason MD, Rouviere O, De Santis M, Willemse PM, van Poppel H, Mottet N. Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018. Eur Urol. 2018;74(1):84–91. van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM, Lam TB, Mason MD, Rouviere O, De Santis M, Willemse PM, van Poppel H, Mottet N. Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018. Eur Urol. 2018;74(1):84–91.
2.
go back to reference Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, Nguyen PL, Trachtenberg J, Polascik TJ. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2014;66:732–51.CrossRef Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, Nguyen PL, Trachtenberg J, Polascik TJ. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2014;66:732–51.CrossRef
3.
go back to reference Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M. New and established Technology in Focal Ablation of the prostate: a systematic review. Eur Urol. 2017;71:17–34.CrossRef Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M. New and established Technology in Focal Ablation of the prostate: a systematic review. Eur Urol. 2017;71:17–34.CrossRef
4.
go back to reference Giannarini G, Gandaglia G, Montorsi F, Briganti A. Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer? J Clin Oncol. 2014;32:1299–301.CrossRef Giannarini G, Gandaglia G, Montorsi F, Briganti A. Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer? J Clin Oncol. 2014;32:1299–301.CrossRef
5.
go back to reference Valerio M, Emberton M, Ahmed HU. Focal therapy will become a standard option for selected men with localized prostate cancer. J Clin Oncol. 2014;32:3680–1.CrossRef Valerio M, Emberton M, Ahmed HU. Focal therapy will become a standard option for selected men with localized prostate cancer. J Clin Oncol. 2014;32:3680–1.CrossRef
6.
go back to reference Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002;60:264–9.CrossRef Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002;60:264–9.CrossRef
7.
go back to reference Algaba F, Montironi R. Impact of prostate cancer multifocality on its biology and treatment. J Endourol. 2010;24:799–804.CrossRef Algaba F, Montironi R. Impact of prostate cancer multifocality on its biology and treatment. J Endourol. 2010;24:799–804.CrossRef
8.
go back to reference Ahmed HU, Arya M, Freeman A, Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol. 2012;13:e509–17.CrossRef Ahmed HU, Arya M, Freeman A, Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol. 2012;13:e509–17.CrossRef
9.
go back to reference Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol. 2003;170:459–63.CrossRef Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol. 2003;170:459–63.CrossRef
10.
go back to reference de Rooij M, Hamoen EH, Futterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol. 2014;202:343–51.CrossRef de Rooij M, Hamoen EH, Futterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol. 2014;202:343–51.CrossRef
11.
go back to reference Futterer JJ. Multiparametric MRI in the detection of clinically significant prostate Cancer. Korean J Radiol. 2017;18:597–606.CrossRef Futterer JJ. Multiparametric MRI in the detection of clinically significant prostate Cancer. Korean J Radiol. 2017;18:597–606.CrossRef
12.
go back to reference Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A. Can clinically significant prostate Cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68:1045–53.CrossRef Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A. Can clinically significant prostate Cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68:1045–53.CrossRef
13.
go back to reference Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, Huang J, Margolis DJ, Raman SS, Reiter RE. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015;67:569–76.CrossRef Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, Huang J, Margolis DJ, Raman SS, Reiter RE. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015;67:569–76.CrossRef
14.
go back to reference Kang DI, Chung JI, Ha HK, Min K, Yoon J, Kim W, Seo WI, Kang P, Jung SJ, Kim IY. Korean prostate cancer patients have worse disease characteristics than their American counterparts. Asian Pac J Cancer Prev. 2013;14:6913–7.CrossRef Kang DI, Chung JI, Ha HK, Min K, Yoon J, Kim W, Seo WI, Kang P, Jung SJ, Kim IY. Korean prostate cancer patients have worse disease characteristics than their American counterparts. Asian Pac J Cancer Prev. 2013;14:6913–7.CrossRef
15.
go back to reference Jeong IG, Dajani D, Verghese M, Hwang J, Cho YM, Hong JH, Kim CS, Ahn H, Ro JY. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: a retrospective cohort study of radical prostatectomy. Urol Oncol. 2016;34:3.e9–14.CrossRef Jeong IG, Dajani D, Verghese M, Hwang J, Cho YM, Hong JH, Kim CS, Ahn H, Ro JY. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: a retrospective cohort study of radical prostatectomy. Urol Oncol. 2016;34:3.e9–14.CrossRef
16.
go back to reference Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. Jama. 1994;271:368–74.CrossRef Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. Jama. 1994;271:368–74.CrossRef
17.
go back to reference Perera M, Lawrentschuk N, Bolton D, Clouston D. Comparison of contemporary methods for estimating prostate tumour volume in pathological specimens. BJU Int. 2014;113(Suppl 2):29–34.CrossRef Perera M, Lawrentschuk N, Bolton D, Clouston D. Comparison of contemporary methods for estimating prostate tumour volume in pathological specimens. BJU Int. 2014;113(Suppl 2):29–34.CrossRef
18.
go back to reference Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol. 1996;180:295–9.CrossRef Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol. 1996;180:295–9.CrossRef
19.
go back to reference Ruijter ET, Miller GJ, van de Kaa CA, van Bokhoven A, Bussemakers MJ, Debruyne FM, Ruiter DJ, Schalken JA. Molecular analysis of multifocal prostate cancer lesions. J Pathol. 1999;188:271–7.CrossRef Ruijter ET, Miller GJ, van de Kaa CA, van Bokhoven A, Bussemakers MJ, Debruyne FM, Ruiter DJ, Schalken JA. Molecular analysis of multifocal prostate cancer lesions. J Pathol. 1999;188:271–7.CrossRef
20.
go back to reference Mouraviev V, Sun L, Madden JF, Mayes JM, Moul JW, Polascik TJ. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology. 2007;70:1141–5.CrossRef Mouraviev V, Sun L, Madden JF, Mayes JM, Moul JW, Polascik TJ. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology. 2007;70:1141–5.CrossRef
21.
go back to reference Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int. 2010;106:1607–11.CrossRef Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int. 2010;106:1607–11.CrossRef
22.
go back to reference Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis. 2011;14:46–52.CrossRef Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis. 2011;14:46–52.CrossRef
23.
go back to reference Crawford ED, Wilson SS, Torkko KC, Hirano D, Stewart JS, Brammell C, Wilson RS, Kawata N, Sullivan H, Lucia MS, Werahera PN. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int. 2005;96:999–1004.CrossRef Crawford ED, Wilson SS, Torkko KC, Hirano D, Stewart JS, Brammell C, Wilson RS, Kawata N, Sullivan H, Lucia MS, Werahera PN. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int. 2005;96:999–1004.CrossRef
24.
go back to reference Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol. 2009;27:4321–6.CrossRef Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol. 2009;27:4321–6.CrossRef
25.
go back to reference Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013;73:778–87.CrossRef Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013;73:778–87.CrossRef
26.
go back to reference Singh PB, Anele C, Dalton E, Barbouti O, Stevens D, Gurung P, Arya M, Jameson C, Freeman A, Emberton M, Ahmed HU. Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. Eur Urol. 2014;66:12–9.CrossRef Singh PB, Anele C, Dalton E, Barbouti O, Stevens D, Gurung P, Arya M, Jameson C, Freeman A, Emberton M, Ahmed HU. Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. Eur Urol. 2014;66:12–9.CrossRef
27.
go back to reference Ahmed HU, Dickinson L, Charman S, Weir S, McCartan N, Hindley RG, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal ablation targeted to the index lesion in multifocal localised prostate Cancer: a prospective development study. Eur Urol. 2015;68:927–36.CrossRef Ahmed HU, Dickinson L, Charman S, Weir S, McCartan N, Hindley RG, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal ablation targeted to the index lesion in multifocal localised prostate Cancer: a prospective development study. Eur Urol. 2015;68:927–36.CrossRef
28.
go back to reference Tran M, Thompson J, Bohm M, Pulbrook M, Moses D, Shnier R, Brenner P, Delprado W, Haynes AM, Savdie R, Stricker PD. Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy. BJU Int. 2016;117:48–54.CrossRef Tran M, Thompson J, Bohm M, Pulbrook M, Moses D, Shnier R, Brenner P, Delprado W, Haynes AM, Savdie R, Stricker PD. Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy. BJU Int. 2016;117:48–54.CrossRef
29.
go back to reference Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007;110:906–10.CrossRef Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007;110:906–10.CrossRef
Metadata
Title
Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy
Authors
Young Hyo Choi
Ji Woong Yu
Byong Chang Jeong
Seong Il Seo
Seong Soo Jeon
Hyun Moo Lee
Hwang Gyun Jeon
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2019
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-019-0782-8

Other articles of this Issue 1/2019

Diagnostic Pathology 1/2019 Go to the issue